PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 77 filers reported holding PROQR THRAPEUTICS N V in Q4 2021. The put-call ratio across all filers is 2.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $52,793 | -62.4% | 40,610 | -53.1% | 0.00% | – |
| Q2 2023 | $140,292 | -76.3% | 86,600 | -68.9% | 0.00% | – |
| Q1 2023 | $592,992 | -37.2% | 278,400 | +9.2% | 0.00% | – |
| Q4 2022 | $943,578 | +7763.2% | 255,021 | +1503.9% | 0.00% | – |
| Q3 2022 | $12,000 | -81.5% | 15,900 | -80.8% | 0.00% | – |
| Q2 2022 | $65,000 | +41.3% | 82,765 | +61.3% | 0.00% | – |
| Q1 2022 | $46,000 | -94.6% | 51,300 | -52.0% | 0.00% | – |
| Q4 2021 | $856,000 | -45.0% | 106,818 | -42.5% | 0.00% | – |
| Q3 2021 | $1,555,000 | +438.1% | 185,766 | +333.4% | 0.00% | – |
| Q2 2021 | $289,000 | -72.9% | 42,859 | -73.4% | 0.00% | – |
| Q1 2021 | $1,066,000 | +1422.9% | 161,258 | +1302.1% | 0.00% | – |
| Q2 2020 | $70,000 | 0.0% | 11,501 | -9.9% | 0.00% | – |
| Q1 2020 | $70,000 | -57.8% | 12,758 | -23.8% | 0.00% | – |
| Q4 2019 | $166,000 | +238.8% | 16,748 | +5.3% | 0.00% | – |
| Q1 2018 | $49,000 | -49.0% | 15,905 | -46.8% | 0.00% | – |
| Q4 2017 | $96,000 | – | 29,885 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Privium Fund Management B.V. | 5,344,446 | $18,010,783 | 6.83% |
| M28 Capital Management LP | 1,910,600 | $7,069,220 | 6.74% |
| Opaleye Management Inc. | 1,460,000 | $5,402,000 | 1.88% |
| Ikarian Capital, LLC | 422,625 | $1,563,713 | 0.38% |
| Monaco Asset Management SAM | 165,000 | $610,500 | 0.18% |
| AWM Investment Company, Inc. | 166,667 | $616,668 | 0.09% |
| FRANKLIN STREET ADVISORS INC /NC | 150,000 | $555 | 0.05% |
| Atom Investors LP | 18,522 | $68,531 | 0.03% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3,625,467 | $13,414,228 | 0.03% |
| GSA CAPITAL PARTNERS LLP | 21,514 | $80 | 0.01% |